(3.33)
Based on 20 studies
| Side Effect | Affected |
|---|---|
| Headache | 6% |
| Dermatitis atopic | 4% |
| Eczema | 4% |
| Eczema nummular | 3% |
Image for illustration purposes only. Actual medication may appear different.
Get Nemluvio
Consult with a board-certified medical professional
Image for illustration purposes only. Actual medication may appear different.
Highlights
Nemolizumab significantly reduces itching (pruritus) in patients with moderate-to-severe atopic dermatitis. In clinical trials, patients saw 40-70% reduction in itch scores after 16 weeks of treatment, with improvements noticeable within the first few days.
| Study Summary | Study Type | Studied Population | Results |
|---|---|---|---|
|
š
Nemolizumab, when used with topical treatments, reduced itching by 43% compared to 21% with placebo after 16 weeks. The medication also improved eczema severity and sleep quality in Japanese patients with moderate-to-severe atopic dermatitis.
|
Clinical Trial |
Total Patients: 215
|
Nemolizumab reduced itching twice as much as placebo |
|
š
Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.
|
Clinical Trial |
Total Patients: 1,728
|
|
|
š
Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.
|
Clinical Trial |
Total Patients: 226
Severity: moderate to severe Age: 18+
|
Nemolizumab, when used with topical treatments, reduced itching by 43% compared to 21% with placebo after 16 weeks. The medication also improved eczema severity and sleep quality in Japanese patients with moderate-to-severe atopic dermatitis.
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsNemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.
Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus.The medication improves skin symptoms and quality of life, including better sleep. Studies showed 45-78% improvement in eczema severity scores over 16-68 weeks of treatment.
| Study Summary | Study Type | Studied Population | Results |
|---|---|---|---|
|
š
Nemolizumab, given as an injection every 4 weeks along with topical treatments, helped reduce itching by 66% and eczema severity by 78% over 68 weeks in patients with moderate-to-severe atopic dermatitis. The improvements lasted even after treatment ended, and the medication was generally safe to use.
|
Clinical Trial |
Total Patients: 303
Severity: moderate to severe Age: ā„13 years
|
Significant reduction in itching maintained over more than a year |
|
š
Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.
|
Clinical Trial |
Total Patients: 1,728
|
Nemolizumab, given as an injection every 4 weeks along with topical treatments, helped reduce itching by 66% and eczema severity by 78% over 68 weeks in patients with moderate-to-severe atopic dermatitis. The improvements lasted even after treatment ended, and the medication was generally safe to use.
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderateātoāsevere pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, longāterm studiesNemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsThe most common side effects are mild and include nasopharyngitis (common cold), upper respiratory tract infections, and worsening of atopic dermatitis. Serious side effects are rare but can include severe allergic reactions.
| Study Summary | Study Type | Studied Population | Results |
|---|---|---|---|
|
š
Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.
|
Clinical Trial |
Total Patients: 226
Severity: moderate to severe Age: 18+
|
|
|
š
Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.
|
Review |
Severity: moderate to severe Age: 13+
|
Continuous improvement and/or maintenance of itching reduction up to 68 weeks |
Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.
Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus.Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.
[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].The medication is given as a subcutaneous injection every 4 weeks. It works by blocking interleukin-31, a protein that triggers itching in atopic dermatitis.
| Study Summary | Study Type | Studied Population | Results |
|---|---|---|---|
|
š
Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.
|
Review |
Severity: moderate to severe Age: 13+
|
Continuous improvement and/or maintenance of itching reduction up to 68 weeks |
|
š
Nemolizumab is a new drug that targets IL-31, which is involved in causing eczema symptoms. The drug shows good results in reducing itch quickly and improving skin condition, with mostly mild side effects.
|
Review |
Severity: not available Age: not available
|
not available |
Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.
[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].Nemolizumab is a new drug that targets IL-31, which is involved in causing eczema symptoms. The drug shows good results in reducing itch quickly and improving skin condition, with mostly mild side effects.
Nemolizumab for atopic dermatitis.Taken every 4 weeks
| Study Summary | Study Type | Studied Population | Results |
|---|
Itch relief in as soon as 48 hours
| Study Summary | Study Type | Studied Population | Results |
|---|
Unique mechanism of action
| Study Summary | Study Type | Studied Population | Results |
|---|
Is Nemluvio Right For Me?
-
You are an adult
-
You have prurigo nodularis (a chronic skin condition that causes intense itching and firm bumps on the skin)
Interested in eczema products?
As a member of the Lemma Health community, you'll stay up to date with research, hear about new products, and get exclusive access to discounts.
Personalized Eczema CareāPowered by AI
AI that understands your skin
Our AI learns from your symptoms, triggers, and lifestyle to recommend treatments tailored to you. As your skin changes, your plan adaptsāfor lasting relief.
Data-backed suggestions in seconds
Instantly analyzes real-world reviews and clinical research to skip months of trial and error. Get trusted, proven treatment ideasāfast.
Doctors who listenāand move fast
Youāre in control. Found a treatment that resonates? Weāll connect you to a dermatologist who respects your plan and helps you get care from home.
How Lemma Health Works
Get Smart, Personalized Recommendations
Skip the guesswork
Our AI reviews thousands of research studies and real-world results to match you with the most effective treatments for your unique skin profile.
Talk to a Dermatologist who Listens ā Fast
Found something you want to try?
Weāll connect you with a board-certified dermatologist who respects your preferences and helps you get what you need without the wait.
Let AI Fine-Tune Your Plan Over Time
Eczema isnāt staticā
and neither is our support
As you log whatās working (or not), our AI adapts your plan to keep improving it. We help you adjust, optimize, and stay ahead of flare-ups.
Your Skin Will Thank You
Take our 2-minute profile quiz and see whatās working for people just like you.
What are others saying?
The following comments are sourced from publicly available forums, including Reddit. They reflect personal opinions and anecdotal experiences, and do not constitute medical advice. Lemma Health does not verify the accuracy, completeness, or authorship of these statements, nor does it endorse any specific treatment, medication, or outcome mentioned. These excerpts are provided for informational purposes only.
No reviews available yet
We collect reviews of treatments from various sources including social media and are not always able to verify whether these have been written by actual patients.